Steve holds a PhD in Biochemistry from the Faculty of Medicine at the University of Toronto, Canada. He worked as a medical scientist for 18 years, within both industry and academia, where his research focused on the discovery of new medicines to treat inflammatory disorders and infectious diseases. Steve recently stepped away from the lab and into science communications, where he’s helping make medical science information more accessible for everyone.
Bacterial and fungal profiles found in fecal samples from people with inflammatory bowel disease (IBD) were able to predict the patients’ responses to the anti-inflammatory therapy infliximab, a study revealed. ... Read more
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended approval of a subcutaneous (under-the-skin) injection of Entyvio (Vedolizumab), the gut-selective maintenance therapy for ... Read more
Maintenance therapy with Entyvio‘s new formulation as a subcutaneous, or under-the-skin injection (SC) led more people with moderate-to-severe, active Crohn’s disease (CD) to achieve clinical remission after one year, compared ... Read more
Biomica announced the start of preclinical studies to test the anti-inflammatory abilities of two of its microbiome-based therapies for inflammatory bowel disease (IBD). The company’s potential microbe treatments aim to restore ... Read more
One year of treatment with Entyvio (vedolizumab) was found to be superior to Humira (adalimumab) in achieving disease remission in people with ulcerative colitis (UC), a common form of inflammatory bowel disease (IBD), Takeda ... Read more
Galapagos NV‘s potential new therapy for inflammatory bowel disease (IBD) — which stimulates anti-inflammatory signals while inhibiting pro-inflammatory ones — will move into Phase 1 clinical testing, the company announced. ... Read more